newsfilter
← Latest News
PR Newswire·

K36 Therapeutics Announces Presentation on KTX-1001 for Relapsed and Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

K36 Therapeutics, Inc. ("K36"), a clinical-stage biotech company focused on developing its first-in-class MMSET inhibitor KTX-1001 for t(4;14)...